ClinicalTrials.gg
RecruitingNCT06089473Updated Dec 3, 2025

Virtual Home-based Physical Pre-habilitation in Kidney Transplant Candidates

An interventional study of Intervention Group: Exercise and education. and Usual Care Only in Kidney Disease, End-Stage, Frailty and Transplant;Failure,Kidney, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Kidney Failure, Chronic with a site in Canada — 20 open to participants now, 28 under way, 4 of them phase 3. Kidney Failure, Chronic · Canada.

Planned enrollment
83rd of 110
30 · median 79
Started
2024
with 7 others
No phase
50 of 134
9 open now
Primary completion
2026-08
later than 7 of 27 live
Registered
123rd of 134
by date
Lead sponsor
6 of 134
McGill University Health Centre/Research Institute of the McGill University Health Centre

Among the 134 studies in Kidney Failure, Chronic with a site in Canada, this one is the 83rd largest by planned enrollment of the 110 interventional ones that give a count, is one of 8 that started in 2024, is one of 50 with no phase, reaches primary completion later than 7 of the 27 other live ones, and was the 123rd registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

20 of the 134 studies in Kidney Failure, Chronic with a site in Canada are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Kidney Failure, Chronic with a site in Canada, or all of them as a file.
02

Study summary

The goal of this RCT is to address the feasibility of conducting a 12-week virtual pre-habilitation intervention, which includes exercise and education, in kidney transplant candidates. The intervention also includes a 5-month maintenance phase with independent home exercises (maximum of 8 months of intervention/ended early if the participant undergoes a kidney transplant). The main questions it aims to answer are:

  • estimate the proportion of screened patients who meet eligibility criteria
  • estimate the proportion of eligible patients who consent to randomization
  • estimate the proportion of patients who adhere to the interventions
  • estimate follow-up completion rates
  • inform the calculation of sample size requirements for a full-scale RCT
  • assess the acceptability of the intervention by the participants.

Participants in the control group will receive usual outpatient care.

Read the detailed description

While waiting for kidney transplant, candidates face many challenges related to their physical health. These physical impairments are strongly associated with pre- and post-transplant mortality and morbidity. Pre-habilitation is the process of enhancing patient functional capacity prior to surgery with the objective of improving tolerance for the stressor. In the context of this protocol, pre-habilitation is referring to an exercise-based program with education prior to transplant. Pre-habilitation has been shown to contribute to a reduction of postoperative recovery time and quicker return to functional ability after thoracic and abdominal surgery. There is, however, limited evidence for the effects of pre-habilitation in kidney transplant candidates.

The investigators are following up previous work conducted with a very small (n=8) pilot pre-post study on pre-habilitation (MUHC REB number = 2020-5951) specifically with kidney transplant candidates. The results were encouraging.

The current multicenter pilot randomized controlled trial (RCT) will address the following research question: is it feasible to conduct a full-scale multicenter RCT to assess the comparative effectiveness of a virtual home-based pre-habilitation versus usual care for kidney transplant candidates? The investigators' specific objectives are to: (1) estimate the proportion of screened patients who meet eligibility criteria, (2) estimate the proportion of eligible patients who consent to randomization, (3) estimate the proportion of patients who adhere to the interventions, (4) estimate follow-up completion rates, (5) inform the calculation of sample size requirements for a full-scale RCT and, (6) assess the acceptability of the intervention by the participants. The assessor-blind pilot RCT will be conducted in three hospitals in Canada: MUHC, CHUM and University of Alberta Hospital. Eligible subjects will be randomized 1:1 to receive either i) virtual home-based multimodal pre-habilitation plus usual outpatient care, or ii) usual outpatient care. Participants will be drawn from the transplant clinics at the 3 sites, and the investigators aim to recruit 30 participants (22 of which will be recruited from MUHC over 9 months).

While some of the assessment appointments will be in person, the intervention is virtual so as not to burden the participants with extra hospital visits. The exercise portion of the study will include a 12-week virtual home-based supervised exercise program and a 5-month maintenance phase with independent home exercises (maximum of 8 months of intervention/ended early if the participant undergoes transplantation). Participants in the intervention group will also watch short educational videos about their kidney, assessment and waitlist, surgery and recovery, medication, and their new life after transplantation. Additionally, participants will be provided a document (PDF) of evidence-based strategies to help cope with stress.

Patients in the control group will receive usual outpatient care. All participants in the control group will receive educational resources received by intervention group participants at trial completion.

All participants will undergo a nutrition screening and will complete questionnaires regarding anxiety and depression. The corresponding transplant team will be notified should participants score 'abnormal' on these assessment tools. Additionally, all study participants will be asked questions regarding the following: whether they have had previous nutritional counselling or received any nutritional interventions, whether they have nutritional concerns/needs, whether they face any challenges in maintaining a balanced diet, whether they have had previous psychological counseling as part of the transplant assessment. This information will be collected as part of a needs assessment to inform inclusion of a nutritional and psychological interventions in subsequent trials.

03

Conditions studied

  • Kidney Disease, End-Stage
  • Frailty
  • Transplant;Failure,Kidney
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • consecutive individuals with end stage kidney disease (ESKD) (aged ≥18 years), classified as pre-frail (1-2 points), frail (3-4 points) or very frail (5 points) on the Fried's frailty phenotype and who are accepted or in the process of being accepted to enter in the deceased or living donor KT waiting list of the McGill University Health Centre (MUHC), Centre Hospitalier de l'Université de Montreal (CHUM) or University of Alberta Hospital (UAH) for first-time transplantation or re-transplantation
  • English or French speakers
  • is technologically capable of connecting (either independently or through household members/next-of-kin) with an online videoconferencing platform through an e-mail invitation (Patients who do not have access to internet will borrow a tablet with internet for the period of the study)

Exclusion criteria

Exclusion Criteria:

  • Individuals who:
  • are classified as robust (0 points) on their Fried's frailty phenotype score
  • are participating in a structured exercise program (hospital-based or home-based or another trial)
  • are waiting for kidney-pancreas or kidney-liver transplant as those have much longer waiting time
  • are hospitalized for any reason during the assessment for eligibility
  • have a cPRA (calculated panel reactive antibodies) >95% and are on the highly sensitized exchange program and expected to have a prolonged waiting times on the waiting list
  • are expected to have a transplant before the end of the 12 week-intervention (e.g. individuals who will receive an organ from a living donor or are type A blood
  • have pre-existing or newly identified significant cognitive impairment
  • have pre-existing or newly identified cardiac, musculoskeletal, neuropathy or neurological condition that might affect their exercise performance or otherwise render rehabilitation participation unsafe
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Experimental: Pre-habilitation plus usual outpatient care

    An intervention including exercise and education.

    Other: Intervention Group: Exercise and education.

  • Other
    No Intervention: Usual outpatient care

    The control group will receive usual outpatient care provided to kidney transplant candidates. All participants in the control group will receive educational resources received by intervention group participants at trial completion.

    Other: Usual Care Only

Interventions

  • OtherIntervention Group: Exercise and education.

    * Exercise Intervention: 12-weeks of supervised, individualized virtual exercise sessions, delivered by an accredited kinesiologist. Independent unsupervised sessions start at week 5. After 12 weeks, a 5-month maintenance phase is followed, continuing to exercise three times weekly for 30 minutes per session. * Education: Prior to each zoom session with the kinesiologist (starting on week 2), participants will watch short educational videos. Additionally, participants will be provided a document (PDF) of evidence-based strategies to help cope with stress.

  • OtherUsual Care Only

    Usual Care for kidney transplant candidates, which may include medical visits, nutrition, and psychological support.

06

What researchers measure

Primary outcomes

  1. Proportion of screened patients who meet eligibility criteria

    Data generated from this pilot RCT will inform the feasibility of a full-scale RCT by testing the study procedures; therefore, no inferential statistical analyses will be performed to compare groups. Socio-demographic, anthropometric and clinical data will be described using means and standard deviation or median and interquartile range for continuous variables and number and percentage for categorical variables. The variables will be presented at baseline, end of the 12 weeks (induction phase), at 6 months (during maintenance phase), at 8 months (end of maintenance phase) at 3-month post-transplant. Descriptive statistics (frequencies and percentages) will be used to report the feasibility and safety outcomes.

    Time frame: at 12 months

  2. Proportion of eligible patients who consent to randomization

    Data generated from this pilot RCT will inform the feasibility of a full-scale RCT by testing the study procedures; therefore, no inferential statistical analyses will be performed to compare groups. Socio-demographic, anthropometric and clinical data will be described using means and standard deviation or median and interquartile range for continuous variables and number and percentage for categorical variables. The variables will be presented at baseline, end of the 12 weeks (induction phase), at 6 months (during maintenance phase), at 8 months (end of maintenance phase) at 3-month post-transplant. Descriptive statistics (frequencies and percentages) will be used to report the feasibility and safety outcomes.

    Time frame: at 12 months

  3. Proportion of patients who adhere to the interventions

    Data generated from this pilot RCT will inform the feasibility of a full-scale RCT by testing the study procedures; therefore, no inferential statistical analyses will be performed to compare groups. Socio-demographic, anthropometric and clinical data will be described using means and standard deviation or median and interquartile range for continuous variables and number and percentage for categorical variables. The variables will be presented at baseline, end of the 12 weeks (induction phase), at 6 months (during maintenance phase), at 8 months (end of maintenance phase) at 3-month post-transplant. Descriptive statistics (frequencies and percentages) will be used to report the feasibility and safety outcomes.

    Time frame: at 12 months

  4. Rate of follow-up completion as assessed by number of randomized patients completing assessments pre- and post-induction phase.

    Data generated from this pilot RCT will inform the feasibility of a full-scale RCT by testing the study procedures; therefore, no inferential statistical analyses will be performed to compare groups. Socio-demographic, anthropometric and clinical data will be described using means and standard deviation or median and interquartile range for continuous variables and number and percentage for categorical variables. The variables will be presented at baseline, end of the 12 weeks (induction phase), at 6 months (during maintenance phase), at 8 months (end of maintenance phase) at 3-month post-transplant. Descriptive statistics (frequencies and percentages) will be used to report the feasibility and safety outcomes. Completeness to follow-up will be compared between trial arms.

    Time frame: at 12 months

Secondary outcomes

  1. Rate of change in frailty status as assessed by Fried's phenotype method

    Frailty status as measured at the timepoints described below will use the Fried's phenotype method, identified by 3 or more of the following criteria. (please see each component outlined as its own outcome measure). 1. Weight loss 2. Weakness will be assessed using the handgrip strength test ith cut-off values provided by the Frailty index to determine weakness. 3. Exhaustion: 4. Slow gait: 5. Low physical activity: Scoring for the Fried Phenotype: Each indicator can have 0 or 1 as a score, resulting in a total of maximum 5 points, where 0 is being robust, 1-2 pre-frail, 3-4 frail and 5 very frail.

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant

  2. Rate of change in bodyweight obtained from electronic medical chart (contributing to frailty status score for Fried's phenotype method).

    Weight loss (of \> 10 lbs over 6 months): obtained from the patient or chart.

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant

  3. Rate of change in handgrip strength as assessed by hand dynamometer (contributing to frailty status score for Fried's phenotype method).

    Weakness will be assessed using the handgrip strength test (Jamar hydraulic hand Dynamometer). Patients will do six measurements (three times for each hand, with a rest break of 30 seconds between each). The highest measurement will be compared with cut-off values provided by the Frailty index to determine weakness.

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant

  4. Incidence of exhaustion as assessed by Center for Epidemiological Studies Depression (CES-D) (contributing to frailty status score for Fried's phenotype method).

    Exhaustion will be measured by self-reported information based on two questions relating to feeling unusually tired and/or weak, taken from the Center for Epidemiological Studies Depression (CES-D) scale.

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant

  5. Rate of change in gait speed as assessed by the 4-metre gait speed test (contributing to frailty status score for Fried's phenotype method).

    Slow gait: the 4-meter gait speed test will be used to analyze walking time. Participants will be timed as they walk 4 metres at their usual walking pace.

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant

  6. Rate of change in low physical activity status as assessed by the Rapid Assessment of Physical Activity (RAPA) questionnaire (contributing to frailty status score for Fried's phenotype method).

    Low physical activity: energy expenditure weekly rate calculated using the Rapid Assessment of Physical Activity (RAPA) questionnaire; its 7 items assess habits of volume and intensity of weekly exercise. The score will determine whether participants are active or under-active. The scale ranges from 1 (sedentary) to 7 (active). A score of 5 (under-active regular) or less qualifies as low physical activity.

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant

  7. Rate of change in lower-extremity function will be assessed using the short physical performance battery (SPPB).

    The short physical performance battery (SPPB) includes 3 brief physical fitness tests contributing to an overall score demarcating level of frailty. The tests include a 4-metre usual pace walk, a five-repetition sit-to-stand test, and balance tests.

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant

  8. Rate of change in functional exercise capacity as assessed by the 6-minute walk test

    Functional exercise capacity will be measured using the 6-minute walking test (6MWT), which uses the distance walked within 6 minutes in metres. The 6MWT has been shown to be a reliable and viable alternative to the gold standard test (cardiopulmonary exercise test) in individuals with chronic kidney disease.

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant

  9. Rate of change in Health Related Quality of Life scores as assessed by the Kidney Disease Quality of Life Short Form Instrument (KDQOL-SF)

    Kidney Disease Quality of Life Short Form Instrument (KDQOL-SF) is a self-report measure developed for individuals with kidney disease and those on dialysis. It includes both generic (36 items) and disease-specific (43 items) components for the assessment of HRQoL. Life Participation will be assessed using sub-scales of the KDQOL-SF questionnaire which include questions about personal relationships, work, and activities of daily living. The minimum and maximum scores vary by question, as does the scoring for those items. In some of the items, a higher numerical score (5/5) indicates a favourable health state, whereas the opposite is true for other items (1/5) indicates a more favourable health state. The scoring procedure for the KDQOL-SF transforms the numeric values into a 1-100 range, with higher transformed scores reflecting a better quality of life.

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant

  10. Changes in nutrition status as assessed by Patient-Generated Subjective Global Assessment (PG-SGA)

    Patient-Generated Subjective Global Assessment (PG-SGA) Scale Information: this is a patient-scored questionnaire in which participants will note changes in food intake, appetite changes, and activity levels. This scale ranges from 0 (no problems) to 36 (worst problem), with a higher score reflecting a greater risk for malnutrition. A score of 9 or above indicates a need for nutritional intervention.

    Time frame: For those who receive a transplant within study period: baseline and 3-months post-transplant. For those who do not receive a transplant during study period: baseline and 8-months.

  11. Rate of change in body composition as measured by Bioelectrical Impedance

    Bioelectrical impedance will measure measure body composition through phase angle for participants from CHUM and MUHC (not UAH). Phase angle will be the measure used, representing the ratio of resistance to reactance, as an angle. This is part of the nutrition assessment/overall nutrition status.

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant.

  12. Concentration of serum phosphorus (mmol/L)

    At the end of the study, biochemistry will be retrospectively obtained from the participant's medical chart for those occurring within 2 weeks of the scheduled assessment dates found below:

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant.

  13. Concentration of serum potassium (mmol/L)

    At the end of the study, biochemistry will be retrospectively obtained from the participant's medical chart for those occurring within 2 weeks of the scheduled assessment dates found below:

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant.

  14. Percentage of serum A1C

    At the end of the study, biochemistry will be retrospectively obtained from the participant's medical chart for those occurring within 2 weeks of the scheduled assessment dates found below:

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant.

  15. Incidence of anxiety as assessed by Generalized Anxiety Disorder Seven-Item Scale (GAD-7)

    Generalized Anxiety Disorder Seven-Item Scale (GAD-7): this is a 7-question self-report questionnaire completed by participants at the timepoints specified below, indicating the possibility of presence of anxiety. The GAD-7 ranges from 0 to 21, with a lower score indicating minimal anxiety, and a higher score indicating severe anxiety.

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant.

  16. Incidence of depression as assessed by the Patient Health Questionnaire (PHQ-8)

    Patient Health Questionnaire (PHQ-8); this is an 8-question self-report questionnaire completed by participants at the timepoints specified below, indicating the possibility of presence of depression. The PHQ-8 ranges from 0 to 24, with a higher score indicating worse health outcomes. Specifically, a score of 3-6/6 for the first 2 questions indicates anxiety, and a score of 3-6/6 on the last 2 questions indicates depression. Higher scores indicate indicate increasing severity of anxiety or depression.

    Time frame: At baseline, post-induction phase (12 weeks), at 6 months, at 8 months, at 3-month post-transplant.

  17. Level of safety as assessed by number/severity of recorded adverse events related to the intervention

    All adverse events will be recorded. Upon review by the investigator, adverse events will be categorized by "related to the intervention" or "unrelated to the intervention" and categorized into three categories: musculoskeletal (e.g., pain, fall), cardiovascular or kidney related. Adverse events will be graded in terms of severity (Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening; and Grade 5: Death).

    Time frame: from recruitment to end of intervention

  18. Trends identified in post-transplant recovery trajectory as sourced from electronic medical chart information

    Information collected will include (1) intensive care unit length of stay, (2) hospital length of stay, (3) number of readmissions to hospital within 3 months after the surgery, (4) discharge destination, (5) allograft function.

    Time frame: at 3-month post-transplant

  19. Level of acceptability of the intervention as assessed by quantitative semantic differential scale

    Acceptability of the intervention will be assessed in a subset of patients in the intervention group using both quantitative and qualitative data. Quantitative data will include results from a semantic differential scale and from the closed-ended questions of a semi-structured telephone interview (see outcome measure 25). Based on the semantic differential scale, the intervention will be acceptable if a total score of a minimum of 16 is obtained.

    Time frame: Post-induction phase (at 12-weeks), and at 8-months

  20. Level of acceptability of the intervention as assessed by qualitative author-generated questionnaire

    Acceptability of the intervention will be assessed in a subset of patients in the intervention group using both quantitative and qualitative data. Quantitative data will include results from a semantic differential scale (see outcome measure 23) and from the closed-ended questions of a semi-structured author-generated telephone questionnaire (guided by previous usability/acceptability studies).

    Time frame: at 8-months

07

Study locations

2 of 2 sites recruiting
  • Centre de recherche - Centre Hospitalier de l'Université de Montréal (CRCHUM)
    Montreal, Quebec H2X 0A9, Canada
    Recruiting
  • Research Institute - McGill University Health Centre (RI-MUHC)
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Summary results will be available on the trial registry site within 12 months from the last visit of the last participant. Other data will be shared on request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Data will be available within 12 months from the last visit of the last participant.

Access criteria: Access to anonymized IPD can be requested by researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Aug 2026, 21 months after the start.

Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 21 months is close to that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2023
First posted
Oct 18, 2023
StartActual
Nov 2, 2024
Primary completionEst.
Aug 2026
CompletionEst.
Feb 2027
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06089473
Collaborators
The Kidney Foundation of Canada
Responsible party
Tania Janaudis-Ferreira (Scientist, Translational Research in Respiratory Diseases Program, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Oct 18, 2023
Start date
Nov 2, 2024
Primary completion
Aug 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Dec 3, 2025

Study contacts

Tania Janaudis-Ferreira, PhD
Contact
tania.janaudis-ferreira@mcgill.ca
514-619-0871
Amanda Rizk, PhD
Contact
amanda.rizk@rimuhc.ca
514-885-0668
Tania Janaudis-Ferreira, PhD
principal investigator · Research Institute of McGill University Health Centre (RI-MUHC)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion